Recent News

• 07.10.2026 - Palisade Bio to Participate in the Leerink Partners Therapeutics Forum
• 06.29.2026 - Palisade Bio Receives FDA Clearance of IND for PALI-2108 and Plans to Initiate Global Phase 2 ASCENTRA-UC Study in Ulcerative Colitis
• 06.11.2026 - Palisade Bio Welcomes Biopharmaceutical Industry Veterans Robert Baltera and Jordan Zwick to its Board of Directors
• 06.09.2026 - Palisade Bio to Present on the Potential of PALI-2108 for Fibrostenotic Crohn’s Disease at New York Academy of Sciences Symposium
• 05.27.2026 - Palisade Bio to Participate in the Jefferies Global Healthcare Conference
• 05.12.2026 - Palisade Bio Reports First Quarter 2026 Financial Results and Highlights Continued Clinical Progress of PALI-2108
• 05.05.2026 - Palisade Bio Reports Additional Phase 1a/b Data Demonstrating Colon-Targeted Exposure and Sustained IC90 Coverage Supporting Once-Daily Dosing in Ulcerative Colitis
• 04.16.2026 - Palisade Bio Announces Abstract Selected for Poster Presentation at Digestive Disease Week (DDW) 2026
• 04.08.2026 - Palisade Bio to Present at the Needham & Co. 25th Annual Healthcare Conference
• 03.30.2026 - Palisade Bio Reports Positive Topline Data from Phase 1b Clinical Study of PALI-2108 in Fibrostenotic Crohn’s Disease

Recent Filings

• 07.10.2026 - 4 Statement of changes in beneficial ownership of securities
• 07.08.2026 - 4 Statement of changes in beneficial ownership of securities
• 07.08.2026 - 4 Statement of changes in beneficial ownership of securities
• 07.08.2026 - 4 Statement of changes in beneficial ownership of securities
• 07.07.2026 - 144 Report of proposed sale of securities
• 07.07.2026 - 144 Report of proposed sale of securities
• 07.06.2026 - 4 Statement of changes in beneficial ownership of securities
• 06.18.2026 - 4 Statement of changes in beneficial ownership of securities
• 06.18.2026 - 3 Initial statement of beneficial ownership of securities
• 06.12.2026 - 4 Statement of changes in beneficial ownership of securities